估算难治性转移性结直肠癌患者12周死亡概率:Colon Life列线图
研究基于411例ECOG体能状态≤2的难治性转移性结直肠癌患者构建列线图,用于预测评估后12周内死亡概率。列线图纳入体能状态、原发肿瘤切除、乳酸脱氢酶值和腹膜受累四个变量,在开发集和验证集中区分度C指数均为0.778。作者认为该列线图及免费手机应用可能有助于晚期治疗的患者选择和临床试验入组。
要点
- Colon Life列线图基于体能状态、原发肿瘤切除、乳酸脱氢酶值和腹膜受累四个易采集变量预测12周死亡概率。
- 开发集与验证集区分度C指数均为0.778。
- 作者认为该工具可能改善难治性转移性结直肠癌后线治疗的患者选择并协助临床试验入组。
核心结论
- 作者认为该列线图可能是预测难治性转移性结直肠癌患者12周内死亡概率的有用工具。
- 基于四个易采集变量的Colon Life列线图及免费手机应用可能改善后线治疗的患者选择并协助该领域临床试验入组。
研究设计与样本
- 开发集为411例接受瑞戈非尼、TAS-102或其他治疗的ECOG体能状态≤2的难治性转移性结直肠癌患者。
- 使用随机森林模型筛选候选预后变量,并纳入二元逻辑回归模型构建列线图。
- 对列线图进行外部验证,并在开发集(内部验证)和验证集(外部验证)上通过校准和区分能力(Harrell C指数)评估其性能。
主要发现
- 列线图纳入四个变量:体能状态(P < 0.0001)、原发肿瘤切除(P = 0.027)、乳酸脱氢酶值(P = 0.0001)和腹膜受累(P = 0.081)。
- 开发集区分能力高,C = 0.778。
- 验证集区分能力得到确认,C = 0.778。
- 验证集总体结局更好,因接受瑞戈非尼或TAS-102的患者比例更高(46% vs 34%;P < 0.0001)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Regorafenib and TAS-102 have recently demonstrated statistically significant survival gains in patients with refractory metastatic colorectal cancer (mCRC). Life expectancy ≥12 weeks was an inclusion criterion in registrative trials, and the identification of proper clinical selection tools for the daily use of these drugs in heavily pre-treated patients is needed to improve the cost-benefit ratio. We aimed at building a nomogram able to predict death probability within 12 weeks from the date of assessment of refractory mCRC. PATIENTS AND METHODS: Four hundred eleven refractory mCRC patients with ECOG performance status (PS) ≤2 receiving regorafenib, TAS-102 or other treatments were used as developing set. Putative prognostic variables were selected using a random forest model and included in a binary logistic model from which the nomogram was developed. The nomogram was externally validated and its performance was evaluated by examining calibration (how close predictions were to the actual outcome) and discriminative ability (Harrell C index) both on developing (internal validation) and validating (external validation) sets. RESULTS: Four variables were selected and included in the nomogram: PS (P < 0.0001), primary tumor resection (P = 0.027), LDH value (P = 0.0001) and peritoneal involvement (P = 0.081). In the developing set, the nomogram discriminative ability was high (C = 0.778), and was confirmed in the validating set (C = 0.778), where the overall outcome was better as a consequence of the enrichment in patients receiving regorafenib or TAS-102 (46% versus 34%; P < 0.0001). CONCLUSIONS: Our nomogram may be a useful tool to predict the probability of death within 12 weeks in patients with refractory mCRC. Based on four easy-to-collect variables, the 'Colon Life' nomogram and free app for smartphones may improve mCRC patients' selection for later-line therapies and assist researchers for the enrollment in clinical trials in this setting.
引用
- Pietrantonio F, Miceli R, Rimassa L, et al. Estimating 12-week death probability in patients with refractory metastatic colorectal cancer: the Colon Life nomogram. Ann Oncol. 2017. PMID: 27864220. doi:10.1093/annonc/mdw627
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。